A5103118978- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Ubiquitin and proteasome pathways
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- Protease and Inhibitor Mechanisms
- MicroRNA in disease regulation
- Circular RNAs in diseases
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Protein Kinase Regulation and GTPase Signaling
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer-related molecular mechanisms research
- Medical Imaging and Pathology Studies
- Mechanisms of cancer metastasis
- Ferroptosis and cancer prognosis
- Protein Tyrosine Phosphatases
- Histiocytic Disorders and Treatments
- Cell Adhesion Molecules Research
- CRISPR and Genetic Engineering
- Coastal wetland ecosystem dynamics
- Genomics and Rare Diseases
- Nanoparticle-Based Drug Delivery
- Liver physiology and pathology
Burning Rock Biotech (China)
2021-2024
Nanjing Drum Tower Hospital
2024
Southwest University
2024
The University of Sydney
2022
Nantong University
2021-2022
BGI Group (China)
2021
State Key Laboratory of Digital Medical Engineering
2019-2020
Southeast University
2019-2020
Advanced Imaging Research (United States)
2013
The University of Texas Southwestern Medical Center
2013
Recently, microRNAs have emerged as regulators of cancer metastasis through acting on multiple signaling pathways involved in metastasis. In this study, we analyzed the level miR-10b and cell motility invasiveness several human esophageal squamous carcinoma lines. Our results reveal a significant correlation with invasiveness. Overexpression KYSE140 cells increased invasiveness, whereas inhibition EC9706 reduced although it did not alter motility. Additionally, identified KLF4, known tumor...
Non-small cell lung cancer (NSCLC) often expresses mutant KRAS together with tumor-associated mutations of the CDKN2A locus, which are associated aggressive, therapy-resistant tumors. Here, we unravel specific requirements for maintenance NSCLC that carries this genotype. We establish extracellular signal-regulated kinase (ERK)/RHOA/focal adhesion (FAK) network is deregulated in high-grade Suppression RHOA or FAK induces death selectively KRAS;INK4A/ARF-deficient cells. Furthermore,...
The TP53 tumor suppressor gene plays an important role in preventing and inhibiting the growth of by regulating cell cycle, apoptosis DNA repair. Meanwhile, is one most frequently altered non-small lung cancer (NSCLC) patients. Mutant (TP53-MUT) may lose activity gain promoting functions, which play risk, therapy resistance poor prognosis. impact TP53-MUT on prognosis NSCLC patients need to be further studied.We obtained genomic clinical data from Cancer Genome Atlas (TCGA). Mutation...
Abstract Background In non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs), higher blood tumor mutational burden (bTMB) was usually associated with better progression-free survival (PFS) and objective response rate (ORR). However, the association between bTMB overall (OS) benefit remains undefined. It has been reported that harboring a high level of circulating DNA (ctDNA) had poor survival. We hypothesized ctDNA-adjusted might predict OS in NSCLC ICIs....
Lung adenocarcinoma (LUAD) is a heterogeneous disease. Our study aimed to understand the unique molecular features of preinvasive invasive LUAD subtypes. We retrospectively analyzed clinical, histopathological, and data 3,254 Chinese patients with lesions (n = 252), minimally adenocarcinomas 479), 2,523). Molecular were elucidated using targeted 68-gene next-generation sequencing panel. findings revealed four lesion-predominant gene mutations, including MAP2K1 insertion-deletions (indels),...
Despite the important breakthroughs of immune checkpoint inhibitors in recent years, objective response rates remain limited. Here, we synthesize programmed cell death protein-1 (PD-1) antibody-iRGD cyclic peptide conjugate (αPD-1-(iRGD)2) through glycoengineering methods. In addition to enhancing tissue penetration, αPD-1-(iRGD)2 simultaneously engages tumor cells and PD-1+ T via dual targeting, thus mediating tumor-specific activation proliferation with mild effects on non-specific cells....
Abstract Background The combination of immune checkpoint inhibitors (ICIs) and chemotherapy has been the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with driver-gene negative. However, efficacy biomarkers ICIs-based therapy are lacking. We aimed to identify potential factors associated outcomes ICIs plus at baseline dynamic changes in peripheral blood. Methods collected plasma samples 51 NSCLC without EGFR/ALK/ROS1 alteration and/or after two cycles...
Intratumor heterogeneity (ITH) has been associated with poor prognosis in advanced non-small cell cancer (NSCLC) patients receiving immune checkpoint blockade (ICB) therapies. However, there is currently no evidence supporting an ITH metric as a predictor of clinical benefit from ICB. The unique advantages blood make it promising material for estimation and relevant applications. This study aims to develop validate blood-based index predicting ICB response.NSCLC the OAK POPLAR trials were...
Given that long non-coding RNAs (lncRNAs) involved in the tumor initiation or progression of endometrium and competing endogenous RNA (ceRNA) plays an important role increasingly more biological processes, lncRNA-mediated ceRNA is likely to function pathogenesis uterine corpus endometrial carcinoma (UCEC). Our present study aimed explore potential molecular mechanisms for prognosis UCEC through a network.The transcriptome profiles corresponding clinical dataset were retrieved from Clinical...
Zooxanthellae and coral can form an intracellular symbiotic system. Yet, little is known about the molecular mechanism underlying this symbiosis. In study, we characterized symbiosis based on analyses of gene expression at single-cell level. Among 9110 single cells, identified 4871 cells detection both zooxanthellae transcripts within a cell. Using bioinformatics tool Seurat, were further clustered into five groups, 52 genes exhibited differential between groups. We proposed index called...
<h3>Background</h3> Treatment responses of immune checkpoint blockade (ICB) in various solid cancers remain suboptimal, largely due to the suppressive nature tumor microenvironment (TIME). Current targeted protein degradation approaches fail achieve satisfactory downregulation molecules across diverse cell types within TIME. <h3>Methods</h3> Aptamer-nanobody chimera was synthesized by conjugating cation-independent mannose-6-phosphate receptor (CI-M6PR) aptamer with a programmed death-ligand...
In recent years, the informatization of educational system has caused a substantial increase in data. Educational data mining can assist identifying factors influencing students’ performance. However, two challenges have arisen field mining: (1) How to handle abundance unlabeled data? (2) identify most crucial characteristics that impact student performance? this paper, semi-supervised feature selection framework is proposed analyze The method semi-supervised, enabling processing...
7552 Background: FGFR-1 is a novel target for therapy in non-small cell lung carcinoma (NSCLC). FGFR1 gene has been shown to be amplified ~20% of squamous carcinomas (SCC) the lung. The frequency copy number gain (CNG) and amplification (GA) adenocarcinoma (AC) unknown, clinicopathological molecular characteristics NSCLC tumors with FGFR1gene increase have not fully described. Methods: We examined (GCN) by fluorescent in-situ hybridization (FISH) protein expression immunohistochemistry 475...
9051 Background: Lung adenocarcinoma (LUAD) is further classified into several histological subtypes with in situ (AIS), minimally invasive (MIA), and (IAC) as the three major according to extent of invasion. AIS has been considered a precursor IAC. Considering significantly higher mutation burden among IAC tumors than tumors, it seems likely that undergo process accumulating various somatic mutations gain ability. To understand gene involved this transformation, we compared mutational...
<p>Supplementary Figure 4 PDF file - 169K, This shows that RHOA activation is essential for the survival of NSCLC expressing mutant KRAS in association with INK4a/ARF or p53 deficiency</p>
<p>Supplementary Figure 7 PDF file - 205K, This shows that pharmacological inhibition of FAK results in suppression NSCLC vivo</p>